Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.

Jones JD, Speer T, Comer SD, Ross S, Rotrosen J, Reid MS.

Am J Drug Alcohol Abuse. 2013 Mar;39(2):86-91. doi: 10.3109/00952990.2012.762372.

2.

Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.

Walsh SL, Heilig M, Nuzzo PA, Henderson P, Lofwall MR.

Addict Biol. 2013 Mar;18(2):332-43. doi: 10.1111/j.1369-1600.2011.00419.x. Epub 2012 Jan 19.

3.

The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.

Kwako LE, George DT, Schwandt ML, Spagnolo PA, Momenan R, Hommer DW, Diamond CA, Sinha R, Shaham Y, Heilig M.

Psychopharmacology (Berl). 2015 Jan;232(1):295-304. doi: 10.1007/s00213-014-3665-4. Epub 2014 Jul 18.

4.

Methadone at tapered doses for the management of opioid withdrawal.

Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M.

Cochrane Database Syst Rev. 2013 Feb 28;2:CD003409. doi: 10.1002/14651858.CD003409.pub4. Review.

PMID:
23450540
5.

Antiemetic studies on the NK1 receptor antagonist aprepitant.

Stoutenburg JP, Raftopoulos H.

J Natl Compr Canc Netw. 2004 Sep;2(5):491-7. Review.

PMID:
19780256
6.

Methadone at tapered doses for the management of opioid withdrawal.

Amato L, Davoli M, Ferri M, Ali R.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003409. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003409.

PMID:
15495052
7.

Methadone at tapered doses for the management of opioid withdrawal.

Amato L, Davoli M, Ferri M, Ali R.

Cochrane Database Syst Rev. 2003;(3):CD003409. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD003409.

PMID:
12917966
8.

Methadone at tapered doses for the management of opioid withdrawal.

Amato L, Davoli M, Ferri M, Ali R.

Cochrane Database Syst Rev. 2002;(2):CD003409. Review. Update in: Cochrane Database Syst Rev. 2003;(2):CD003409.

PMID:
12076479
9.

Alpha2-adrenergic agonists for the management of opioid withdrawal.

Gowing L, Farrell MF, Ali R, White JM.

Cochrane Database Syst Rev. 2014 Mar 31;3:CD002024. doi: 10.1002/14651858.CD002024.pub4. Review.

PMID:
24683051
11.

A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans.

Madsen JL, Fuglsang S.

Aliment Pharmacol Ther. 2008 Apr 1;27(7):609-15. doi: 10.1111/j.1365-2036.2008.03618.x. Epub 2008 Jan 16.

12.

Methadone at tapered doses for the management of opioid withdrawal.

Amato L, Davoli M, Ferri M, Ali R.

Cochrane Database Syst Rev. 2003;(2):CD003409. Review. Update in: Cochrane Database Syst Rev. 2003;(3):CD003409.

PMID:
12804464
13.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

14.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

15.

High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.

Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML.

Psychopharmacology (Berl). 2002 May;161(2):202-12. Epub 2002 Mar 13.

PMID:
11981600
16.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. Epub 2003 Oct 14.

PMID:
14559891
17.

The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma.

Egerer G, Eisenlohr K, Gronkowski M, Burhenne J, Riedel KD, Mikus G.

Br J Clin Pharmacol. 2010 Dec;70(6):903-7. doi: 10.1111/j.1365-2125.2010.03792.x.

18.

Aprepitant--a novel NK1-receptor antagonist.

Patel L, Lindley C.

Expert Opin Pharmacother. 2003 Dec;4(12):2279-96. Review.

PMID:
14640927
19.

A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD.

PLoS One. 2011;6(9):e24180. doi: 10.1371/journal.pone.0024180. Epub 2011 Sep 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk